BS & BP

In a comprehensive investigation by Hypro Diagnostics, bispecific antibodies targeting Her2 were scrutinized for their potential in diverse cancer cell lines. The study honed in on constructing and characterizing these antibodies, highlighting their ability to prompt T cell-driven cell death in Her2-positive cells, even those with minimal Her2 expression. Remarkably, the biparatopic bispecific antibody (Bp-Bs) exhibited amplified affinity to Her2 compared to the monoparatopic version (Bi-Bs), showing significant cytotoxicity against low Her2-expressing cells. This research unveils promising therapeutic prospects for a broader range of patients, potentially revolutionizing treatments for Her2-positive cancers.